荷兰国家环试评估临床病理常规血浆游离DNA提取方法对分子肿瘤分析的影响
该研究将4份高体积诊断性白细胞分离血浆样本和1份人工参考血浆样本分发至14家荷兰实验室,按本地常规SOP提取ccfDNA并集中分析。结果显示不同实验室提取的突变分子水平差异较大,磁珠法较硅胶膜法总ccfDNA产量低29%(P<0.0001)、突变分子回收少41%(P<0.01),但变异等位基因频率和样本完整性相似。结论认为硅胶膜法产量最高,建议 harmonization 提取流程以减少前分析阶段的技术差异。
要点
- 磁珠法较硅胶膜法总ccfDNA产量低29%、突变分子回收少41%
- 不同实验室间突变分子检测水平差异较大,但无持续偏高或偏低表现
- 硅胶膜法总ccfDNA产量最高,更利于低拷贝突变检测
核心结论
- 荷兰实验室间ccfDNA提取前分析流程存在多样性,可能影响临床突变ctDNA检测。
- 硅胶膜法总ccfDNA产量最高,推荐用于检测低拷贝数相关突变。
- 需 harmonization 提取流程以避免前分析阶段技术差异、减少实验室间不一致。
研究设计与样本
- 将4份高体积诊断性白细胞分离血浆样本和1份含预设肿瘤突变的人工参考血浆样本分发至14家荷兰实验室。
- 各实验室按本地常规标准操作程序提取ccfDNA,并在中心参考实验室集中分析突变检测、ccfDNA量和完整性。
主要发现
- 不同实验室提取的ccfDNA样本中突变分子水平差异较大,但无持续高于或低于平均的表现。
- 磁珠法试剂盒较硅胶膜法总ccfDNA产量低29%(P<0.0001),回收的突变分子少41%(P<0.01)。
- 变异等位基因频率和样本完整性与硅胶膜法相似。
- 总ccfDNA产量高于平均的样本中观察到突变分子回收增加。
临床怎么用
- 临床分子肿瘤分析中,为检测低拷贝数相关突变,优先选择硅胶膜法提取ccfDNA。
- 实验室应关注ccfDNA提取流程的标准化与 harmonization,以减少前分析阶段技术差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficient recovery of circulating tumor DNA (ctDNA) depends on the quantity and quality of circulating cell-free DNA (ccfDNA). Here, we evaluated whether various ccfDNA extraction methods routinely applied in Dutch laboratories affect ccfDNA yield, ccfDNA integrity, and mutant ctDNA detection, using identical lung cancer patient-derived plasma samples. METHODS: Aliquots of 4 high-volume diagnostic leukapheresis plasma samples and one artificial reference plasma sample with predetermined tumor-derived mutations were distributed among 14 Dutch laboratories. Extractions of ccfDNA were performed according to local routine standard operating procedures and were analyzed at a central reference laboratory for mutant detection and assessment of ccfDNA quantity and integrity. RESULTS: Mutant molecule levels in extracted ccfDNA samples varied considerably between laboratories, but there was no indication of consistent above or below average performance. Compared to silica membrane-based methods, samples extracted with magnetic beads-based kits revealed an overall lower total ccfDNA yield (-29%; P < 0.0001) and recovered fewer mutant molecules (-41%; P < 0.01). The variant allelic frequency and sample integrity were similar. In samples with a higher-than-average total ccfDNA yield, an augmented recovery of mutant molecules was observed. CONCLUSIONS: In the Netherlands, we encountered diversity in preanalytical workflows with potential consequences on mutant ctDNA detection in clinical practice. Silica membrane-based methodologies resulted in the highest total ccfDNA yield and are therefore preferred to detect low copy numbers of relevant mutations. Harmonization of the extraction workflow for accurate quantification and sensitive detection is required to prevent introduction of technical divergence in the preanalytical phase and reduce interlaboratory discrepancies.
引用
- van der Leest P, Ketelaar EM, van Noesel CJM, et al. Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling. Clin Chem. 2022. PMID: 35616097. doi:10.1093/clinchem/hvac069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。